S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Biden's Plan to Confiscate Your Cash? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Biden's Plan to Confiscate Your Cash? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Biden's Plan to Confiscate Your Cash? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Biden's Plan to Confiscate Your Cash? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
MUST WATCH: Unusual 3-second financial maneuver (Ad)
NASDAQ:PBYI

Puma Biotechnology - PBYI Stock Forecast, Price & News

$3.65
+0.16 (+4.58%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.42
$3.71
50-Day Range
$1.87
$3.84
52-Week Range
$1.60
$7.84
Volume
304,558 shs
Average Volume
476,090 shs
Market Capitalization
$166.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Puma Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
160.3% Upside
$9.50 Price Target
Short Interest
Healthy
4.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Puma Biotechnology in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$174,913 Sold Last Quarter
Proj. Earnings Growth
650.00%
From $0.04 to $0.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.81 out of 5 stars

Medical Sector

54th out of 1,098 stocks

Pharmaceutical Preparations Industry

16th out of 536 stocks

PBYI stock logo

About Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Puma Biotechnology Stock Up 4.6 %

Shares of PBYI Stock traded up $0.16 during mid-day trading on Tuesday, hitting $3.65. The company's stock had a trading volume of 304,558 shares, compared to its average volume of 476,090. Puma Biotechnology has a 52-week low of $1.60 and a 52-week high of $7.84. The business has a 50-day moving average price of $2.90 and a 200 day moving average price of $2.63. The company has a debt-to-equity ratio of 13.63, a quick ratio of 1.47 and a current ratio of 1.57. The stock has a market cap of $166.28 million, a price-to-earnings ratio of -4.24 and a beta of 0.66.

Analyst Upgrades and Downgrades

Several research analysts have commented on PBYI shares. StockNews.com upgraded Puma Biotechnology from a "hold" rating to a "buy" rating in a research note on Monday. HC Wainwright decreased their price objective on Puma Biotechnology from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Friday.

Insider Buying and Selling at Puma Biotechnology

In related news, Director Troy Edward Wilson sold 27,858 shares of the stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $2.58, for a total transaction of $71,873.64. Following the completion of the transaction, the director now directly owns 27,350 shares of the company's stock, valued at $70,563. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, Director Troy Edward Wilson sold 27,858 shares of the stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $2.58, for a total value of $71,873.64. Following the sale, the director now directly owns 27,350 shares in the company, valued at $70,563. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Alan H. Auerbach sold 26,140 shares of the stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $2.63, for a total value of $68,748.20. Following the completion of the sale, the chief executive officer now owns 6,317,952 shares in the company, valued at $16,616,213.76. The disclosure for this sale can be found here. Over the last quarter, insiders sold 67,372 shares of company stock valued at $174,913. Company insiders own 21.20% of the company's stock.

Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Stock News Headlines

Puma Biotechnology Inc News
Puma Biotechnology Q1 2022 Earnings Preview
Puma Biotech: Q4 Earnings Snapshot
Puma Biotechnology Q4 2021 Earnings Preview
Puma Biotechnology's Earnings: A Preview
See More Headlines
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Company Calendar

Last Earnings
11/04/2021
Today
8/09/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PBYI
Employees
196
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+160.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-29,130,000.00
Pretax Margin
-24.28%

Debt

Sales & Book Value

Annual Sales
$253.20 million
Book Value
($0.06) per share

Miscellaneous

Free Float
35,898,000
Market Cap
$166.28 million
Optionable
Optionable
Beta
0.66














PBYI Stock - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings
or view top-rated stocks.

What is Puma Biotechnology's stock price forecast for 2022?

2 brokerages have issued 1 year price targets for Puma Biotechnology's shares. Their PBYI share price forecasts range from $8.00 to $11.00. On average, they predict the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 160.3% from the stock's current price.
View analysts price targets for PBYI
or view top-rated stocks among Wall Street analysts.

How has Puma Biotechnology's stock performed in 2022?

Puma Biotechnology's stock was trading at $3.04 at the beginning of 2022. Since then, PBYI stock has increased by 20.1% and is now trading at $3.65.
View the best growth stocks for 2022 here
.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PBYI earnings forecast
.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.78. The biopharmaceutical company had revenue of $46.20 million for the quarter, compared to analysts' expectations of $53.44 million. Puma Biotechnology had a negative trailing twelve-month return on equity of 843.16% and a negative net margin of 16.68%. The business's quarterly revenue was down 9.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.79) earnings per share.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.13%), Assenagon Asset Management S.A. (0.42%), Russell Investments Group Ltd. (0.27%), Walleye Capital LLC (0.23%), Connor Clark & Lunn Investment Management Ltd. (0.17%) and Prospera Financial Services Inc (0.16%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $3.65.

How much money does Puma Biotechnology make?

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $166.28 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29,130,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Puma Biotechnology have?

Puma Biotechnology employs 196 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501.

This page (NASDAQ:PBYI) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.